Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07470853 · ClinicalTrials.gov registry record · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
A Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer, sponsored by Whitehawk Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 265
- Enrollment target
- 12
- Study locations
NCT07470853 is a Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer that is actively recruiting participants, run by Whitehawk Therapeutics. The registered enrollment target is 265 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (49% lower). The trial reports 12 study locations across 11 states.
The verdict
NCT07470853, a Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer, is actively recruiting participants, sponsored by Whitehawk Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 265 participants
- Enrollment target
- 12
- Study locations
Study Summary
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG HWK-016, MUCIN-16-targeted ADC
Study Locations (12)
New York
- Start - Ny - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
Arkansas
- University of Arkansas - Winthrop P. Rockefeller Cancer Institute - Little Rock
California
- START - Los Angeles - Los Angeles
Florida
- SCRI - Florida Cancer Specialists - Sarasota
Illinois
- St. Francis Medical Center (OSF Healthcare) - Peoria
Michigan
- Karmanos Cancer Center - Detroit
North Carolina
- Atrium Health - Wake Forest - Charlotte
Ohio
- Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2026-03-15 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07470853
The ClinicalTrials.gov registry entry for NCT07470853 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (49% lower). The listed sponsor is Whitehawk Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT07470853 reports 12 study locations spanning 11 distinct geographic areas - top geographies include New York, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT07470853 about?
NCT07470853 is a clinical study titled "A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.". HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study ...
What is the current status of trial NCT07470853?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 265 participants. The study started on 2026-03-15. Estimated completion is 2028-02.
What conditions does trial NCT07470853 study?
This clinical trial studies the following conditions: Endometrial Cancer, Platinum-resistant Ovarian Cancer, PROC.
What interventions are being tested in trial NCT07470853?
The interventions under investigation include: Bevacizumab (DRUG), HWK-016, MUCIN-16-targeted ADC (DRUG).
Who is sponsoring clinical trial NCT07470853?
This trial is sponsored by Whitehawk Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07470853 being conducted?
This trial has 12 study locations across Arkansas, California, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.